⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Form 8-K
sec.gov
AMRX
Amneal Reports Second Quarter 2026 Financial Results
globenewswire.com
AMRX
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
businesswire.com
AMRX
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
globenewswire.com
AMRX
The Alzheimer's Drug Discovery Foundation and The Michael J. Fox Foundation Launch $5 Million Partnership to Target Key Co-Pathologies Driving Alzheimer's and Parkinson's
prnewswire.com
AMRX
Amneal to Report Second Quarter 2026 Results on July 30, 2026
globenewswire.com
AMRX
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
prnewswire.com
AMRX
NVO
AMGN
REGN
GSK
SNY
AZN
PFE
BMRA
MRK
Oncology Precision Medicine Market Trends & Opportunities Forecast 2021-2031
globenewswire.com
AMRX
NTRA
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
globenewswire.com
AMRX
Zambon annuncia il parere positivo del CHMP per Hopledo® (IPX203) nei pazienti adulti con Malattia di Parkinson e fluttuazioni motorie da moderate a severe
businesswire.com
AMRX